# SecuraBio clinical trials: 25 on ClinicalTrials.gov (2026)

Updated November 19, 2026.

ClinicalTrials.gov lists 25 trials with SecuraBio as lead sponsor, 2 of them recruiting or not yet recruiting, as read on November 19, 2026.

## The full list

Clinical trials led by SecuraBio: 25 rows for $5, every trial on ClinicalTrials.gov as read on November 19, 2026. Columns: NCT ID, Title, Sponsor, Sponsor class, Phase, Status, Conditions, Condition groups (MeSH), Interventions, Start date, First posted, Last update posted, Enrollment, Location countries, Read on, Source. Pay by card with no account. Prices exclude VAT. CSV and Excel files with the columns this page does not show (sponsor class, condition groups (MeSH), interventions, start date, last update posted and location countries), which open on your screen as soon as the payment clears and come by email.

Buy: https://specstream.ai/data/clinical-trials/company/securabio

SpecStream is the live web data engine for teams and agents. It reads ClinicalTrials.gov each morning, and this page is that reading. Ask for the sponsors, conditions, phases or places you follow and each new or changed trial arrives in your sheet, CRM, Slack or agent with the sponsor, phase, status and sites.

- Trials: 25
- Recruiting or not yet: 2
- Read on: November 19, 2026

## Trials

The 25 newest of 25, each linked to its ClinicalTrials.gov record. The full list holds every one.

| First posted | NCT ID | Title | Sponsor | Phase | Status | Conditions | Enrollment | Source |
| --- | --- | --- | --- | --- | --- | --- | --- | --- |
| July 20, 2026 | NCT07714187 | A Study of Topical Duvelisib in Participants With Early-stage Mycosis Fungoides | SecuraBio | Phase 1 | Not yet recruiting | Mycosis Fungoides, Cutaneous T-cell Lymphoma | 30 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07714187) |
| July 26, 2024 | NCT06522737 | A Study of Duvelisib Versus Gemcitabine or Bendamustine in Participants With Relapsed/Refractory Nodal T Cell Lymphoma With T Follicular... | SecuraBio | Phase 3 | Recruiting | Lymphoma | 124 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT06522737) |
| April 10, 2020 | NCT04342117 | Observational Trial of Real-World Treatment Utilization and Effectiveness of PI3K-inhibitors in CLL/SLL and FL | SecuraBio | Observational | Terminated | Lymphoma, Small Lymphocytic, Lymphoma, Lymphoma, Non-Hodgkin, Chronic Lymphocytic Leukemia, Follicular Lymphoma | 2 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT04342117) |
| December 10, 2019 | NCT04193293 | A Study of Duvelisib in Combination With Pembrolizumab in Head and Neck Cancer | SecuraBio | Phase 1/2 | Terminated | Head and Neck Squamous Cell Carcinoma | 2 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT04193293) |
| July 30, 2019 | NCT04038359 | A Phase 2 Study Comparing 2 Intermittent Dosing Schedules of Duvelisib in Participants With Indolent Non-Hodgkin Lymphoma | SecuraBio | Phase 2 | Completed | Indolent Non-Hodgkin Lymphoma | 103 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT04038359) |
| December 13, 2017 | NCT03372057 | A Study of Duvelisib in Participants With Relapsed or Refractory Peripheral T-cell Lymphoma (PTCL) | SecuraBio | Phase 2 | Completed | Peripheral T-cell Lymphoma | 156 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT03372057) |
| December 12, 2017 | NCT03370185 | Phase 2 Study of Duvelisib in Previously Treated Patients With Chronic Lymphocytic Leukemia /Small Lymphocytic Lymphoma | SecuraBio | Phase 2 | Withdrawn | Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma | 0 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT03370185) |
| March 17, 2016 | NCT02711852 | A Long-term, Continued Treatment and Follow-up Study in Participants With Hematologic Malignancies Treated With Duvelisib (IPI-145) | SecuraBio | Phase 2 | Completed | Hematologic Malignancy | 19 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT02711852) |
| November 16, 2015 | NCT02605694 | Duvelisib With Rituximab vs R-CHOP in Subjects With Relapsed/Refractory Follicular Lymphoma (FRESCO) | SecuraBio | Phase 2 | Withdrawn | Lymphoma | 0 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT02605694) |
| October 15, 2015 | NCT02576275 | A Study of Duvelisib in Combination With Rituximab and Bendamustine vs Placebo in Combination With Rituximab and Bendamustine in Subjects... | SecuraBio | Phase 3 | Withdrawn | Indolent Non-Hodgkin's Lymphoma, Follicular Lymphoma, Small Lymphocytic Lymphoma, Marginal Zone Lymphoma | 0 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT02576275) |
| March 18, 2015 | NCT02391545 | A Study of Duvelisib in Combination With Rituximab or Obinutuzumab in Subjects With Previously Untreated CD20+ Follicular Lymphoma... | SecuraBio | Phase 1/2 | Terminated | CD20+ Follicular Lymphoma | 55 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT02391545) |
| December 4, 2014 | NCT02307461 | Bioequivalence of Duvelisib and Food Effect on Pharmacokinetics of IPI-145 | SecuraBio | Phase 1 | Completed | Healthy | 103 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT02307461) |
| November 17, 2014 | NCT02292225 | Duvelisib With Obinutuzumab in Patients With CLL/SLL Previously Treated With a BTKi (SYNCHRONY) | SecuraBio | Phase 1 | Terminated | Lymphocytic Leukemia, Chronic, Lymphoma, Small Lymphocytic | 3 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT02292225) |
| July 31, 2014 | NCT02204982 | Study of Duvelisib in Combination With Rituximab vs Rituximab in Subjects With Previously Treated Follicular Lymphoma | SecuraBio | Phase 3 | Terminated | Follicular Lymphoma | 13 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT02204982) |
| March 26, 2014 | NCT02095587 | Duvelisib in Hepatically Impaired Subjects Compared to Healthy Subjects | SecuraBio | Phase 1 | Completed | Hepatic Impairment | 24 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT02095587) |
| January 30, 2014 | NCT02049515 | A Phase 3 Extension Study of Duvelisib and Ofatumumab in Participants With CLL/SLL Previously Enrolled in Study IPI-145-07 | SecuraBio | Phase 3 | Completed | Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma | 99 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT02049515) |
| December 9, 2013 | NCT02004522 | A Phase 3 Study of Duvelisib Versus Ofatumumab in Patients With Relapsed or Refractory CLL/SLL (DUO) | SecuraBio | Phase 3 | Completed | Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma | 319 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT02004522) |
| September 20, 2013 | NCT01947777 | Phase 1 Study in Healthy Subjects to Evaluate the Effect of Rifampin on the Pharmacokinetics of IPI-145 | SecuraBio | Phase 1 | Completed | Healthy | 14 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT01947777) |
| August 20, 2013 | NCT01925911 | Phase 1 Study in Healthy Subjects to Evaluate the Effect of IPI-145 on the Pharmacokinetics of Midazolam | SecuraBio | Phase 1 | Completed | Healthy | 14 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT01925911) |
| June 20, 2013 | NCT01882803 | A Study of Duvelisib in Participants With Refractory Indolent Non-Hodgkin Lymphoma | SecuraBio | Phase 2 | Completed | Indolent Non-Hodgkin Lymphoma | 129 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT01882803) |
| May 10, 2013 | NCT01851707 | A Double-Blind Study Evaluating Duvelisib in Subjects With Moderate to Severe Rheumatoid Arthritis and an Inadequate Response to... | SecuraBio | Phase 2 | Completed | Rheumatoid Arthritis | 322 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT01851707) |
| April 22, 2013 | NCT01836861 | IPI-145 ADME and Absolute Bioavailability Study | SecuraBio | Phase 1 | Completed | Healthy | 6 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT01836861) |
| July 31, 2012 | NCT01653756 | A Phase 2a, Efficacy and Safety Study of Duvelisib in Mild Asthmatic Subjects | SecuraBio | Phase 2 | Completed | Asthma | 50 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT01653756) |
| March 8, 2012 | NCT01549106 | IPI-145 Single Ascending, Multiple Ascending, Food Effect and Drug-Drug-Interaction Study | SecuraBio | Phase 1 | Completed | Healthy Volunteers | 106 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT01549106) |
| November 22, 2011 | NCT01476657 | A Phase 1 Study of Duvelisib in Patients With Advanced Hematologic Malignancies | SecuraBio | Phase 1 | Terminated | Hematologic Malignancies | 210 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT01476657) |

## By phase

| Phase | Trials |
| --- | --- |
| Phase 1 | 9 |
| Phase 1/2 | 2 |
| Phase 2 | 8 |
| Phase 3 | 5 |
| Observational | 1 |

## By status

| Status | Trials |
| --- | --- |
| Completed | 14 |
| Terminated | 6 |
| Withdrawn | 3 |
| Recruiting | 1 |
| Not yet recruiting | 1 |

## Conditions

| Condition group | Trials |
| --- | --- |
| Leukemia, Lymphocytic, Chronic, B-Cell | 6 |
| Lymphoma | 5 |
| Lymphoma, Follicular | 4 |
| Recurrence | 3 |
| Hereditary Sensory and Autonomic Neuropathies | 2 |
| Lymphoma, T-Cell, Peripheral | 2 |
| Hematologic Neoplasms | 2 |
| Immunoblastic Lymphadenopathy | 1 |
| Asthma | 1 |
| Lymphoma, B-Cell, Marginal Zone | 1 |
| Lymphoma, T-Cell | 1 |
| Leukemia | 1 |
| Lymphoma, Non-Hodgkin | 1 |
| Mycosis Fungoides | 1 |
| Lymphoma, T-Cell, Cutaneous | 1 |
| Squamous Cell Carcinoma of Head and Neck | 1 |
| Head and Neck Neoplasms | 1 |
| Arthritis, Rheumatoid | 1 |

## Where the register publishes

- [ClinicalTrials.gov](https://clinicaltrials.gov/)
- [ClinicalTrials.gov API](https://clinicaltrials.gov/data-api/api)

Source: [ClinicalTrials.gov API v2 (U.S. National Library of Medicine)](https://clinicaltrials.gov/data-api/api). U.S. government data; ClinicalTrials.gov terms of use. Studies are as their sponsors registered them on ClinicalTrials.gov, read through its API. Recruiting means the record's overall status is recruiting or not yet recruiting. Condition groups are the MeSH terms ClinicalTrials.gov assigns; a condition page also counts the narrower terms that name it, as the register's own search does (triple negative breast neoplasms are breast neoplasms). Sites are shown as organizations only; no investigator or contact is read or shown.

Free to quote with credit and a link. Copying in bulk needs a [data licence](https://specstream.ai/data/licence).

## Business lists in the United States

- [B2B energy and utility companies in the United States](https://specstream.ai/data/businesses/b2b-energy-and-utility-companies/united-states)
- [Psychiatry practices in the United States](https://specstream.ai/data/businesses/psychiatry-practices/united-states)
- [Hardware and fastener manufacturers in the United States](https://specstream.ai/data/businesses/hardware-and-fastener-manufacturers/united-states)
- [Beer bars in the United States](https://specstream.ai/data/businesses/beer-bars/united-states)
- [Screen printers in the United States](https://specstream.ai/data/businesses/screen-printers/united-states)
- [Industrial equipment manufacturers in the United States](https://specstream.ai/data/businesses/industrial-equipment-manufacturers/united-states)
